Distribuzione geografica
Continente #
EU - Europa 1.675
Totale 1.675
Nazione #
IT - Italia 1.675
Totale 1.675
Città #
Genova 818
Rapallo 530
Genoa 327
Totale 1.675
Nome #
Mepolizumab in severe asthma: evidence in real-life, file e268c4cc-94ad-a6b7-e053-3a05fe0adea1 347
The safety of monoclonal antibodies in asthma, file e268c4cb-4c52-a6b7-e053-3a05fe0adea1 214
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment, file e268c4cb-bac1-a6b7-e053-3a05fe0adea1 206
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma?, file e268c4ca-aac0-a6b7-e053-3a05fe0adea1 179
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma, file e268c4ca-b837-a6b7-e053-3a05fe0adea1 124
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials, file e268c4ca-d88d-a6b7-e053-3a05fe0adea1 111
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma, file e268c4ca-8bbd-a6b7-e053-3a05fe0adea1 95
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience, file e268c4ca-a76b-a6b7-e053-3a05fe0adea1 58
Personalized medicine in allergy, file e268c4ca-b41a-a6b7-e053-3a05fe0adea1 56
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy, file e268c4cb-8cca-a6b7-e053-3a05fe0adea1 56
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations, file e268c4cb-bac0-a6b7-e053-3a05fe0adea1 43
Evolving phenotypes to endotypes: is precision medicine achievable in asthma?, file e268c4cb-d437-a6b7-e053-3a05fe0adea1 23
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy, file e268c4cc-c929-a6b7-e053-3a05fe0adea1 21
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19, file d85263f2-9548-4fd3-882d-90fbcf198e12 18
30 Years Of Sublingual Immunotherapy, file e268c4cb-a6aa-a6b7-e053-3a05fe0adea1 11
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19, file e268c4cc-cdbb-a6b7-e053-3a05fe0adea1 10
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation, file e268c4ca-b7be-a6b7-e053-3a05fe0adea1 9
Biological agents for severe asthma: the evolution of the at-home self-injection approach., file e268c4cd-09dd-a6b7-e053-3a05fe0adea1 9
null, file e268c4cd-7625-a6b7-e053-3a05fe0adea1 9
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life, file e268c4cd-448a-a6b7-e053-3a05fe0adea1 8
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments, file b32882f5-b11f-4739-891f-22dc8680c057 7
Severe asthma, biologicals, and auto-injection: Yes, no, may be!, file e268c4ca-cf3e-a6b7-e053-3a05fe0adea1 6
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy, file f2e2c9fe-0015-4107-81ef-fb915010dffd 6
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life, file e268c4cb-992a-a6b7-e053-3a05fe0adea1 5
One year of mepolizumab. Efficacy and safety in real-life in Italy, file e268c4ca-dcb6-a6b7-e053-3a05fe0adea1 4
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19, file e268c4cf-0177-a6b7-e053-3a05fe0adea1 4
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies, file e268c4c8-85e3-a6b7-e053-3a05fe0adea1 3
Umeclidinium for the treatment of uncontrolled asthma, file e268c4ca-be5b-a6b7-e053-3a05fe0adea1 3
Biosimilars in allergic diseases, file e268c4ca-f702-a6b7-e053-3a05fe0adea1 3
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study, file e268c4cf-0b0c-a6b7-e053-3a05fe0adea1 3
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies, file 5863516d-ea73-4e4b-a554-9c9ddd692662 2
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis, file e268c4ca-a909-a6b7-e053-3a05fe0adea1 2
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases, file e268c4ca-bc18-a6b7-e053-3a05fe0adea1 2
Update on immunotherapy for the treatment of asthma, file e268c4ca-d119-a6b7-e053-3a05fe0adea1 2
Biologicals for severe asthma: what we can learn from real-life experiences?, file e268c4cd-0167-a6b7-e053-3a05fe0adea1 2
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?, file e268c4cd-20f5-a6b7-e053-3a05fe0adea1 2
Severe asthma: One disease and multiple definitions, file e268c4ce-1b89-a6b7-e053-3a05fe0adea1 2
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients, file 12acfdd0-2da7-4c27-aa9c-cdb49471d6f7 1
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps, file 273d79ee-7979-45d3-b592-ebf394755e15 1
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life, file e268c4ca-9a50-a6b7-e053-3a05fe0adea1 1
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma, file e268c4ca-a767-a6b7-e053-3a05fe0adea1 1
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation, file e268c4ca-da59-a6b7-e053-3a05fe0adea1 1
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma, file e268c4ca-e008-a6b7-e053-3a05fe0adea1 1
Current insights in allergen immunotherapy, file e268c4cb-240b-a6b7-e053-3a05fe0adea1 1
The path to personalized medicine in asthma, file e268c4cb-fa23-a6b7-e053-3a05fe0adea1 1
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study, file e268c4cc-1f6c-a6b7-e053-3a05fe0adea1 1
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity, file e268c4cd-c3e1-a6b7-e053-3a05fe0adea1 1
Totale 1.675
Categoria #
all - tutte 3.287
article - articoli 2.760
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.047

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020125 0 0 2 5 13 12 10 16 23 16 16 12
2020/2021248 7 11 10 18 14 12 24 19 20 25 26 62
2021/2022453 43 15 25 68 45 29 20 23 37 36 79 33
2022/2023654 24 47 77 57 52 76 69 51 40 53 69 39
2023/2024194 19 33 42 43 47 10 0 0 0 0 0 0
Totale 1.675